Wed, Jul 23, 2014, 2:11 PM EDT - U.S. Markets close in 1 hr 49 mins


% | $
Click the to save as a favorite.

Abbott Laboratories Message Board

you are viewing a single comment's thread.

view the rest of the posts
  • MrMfztplk MrMfztplk Feb 15, 1998 10:06 PM Flag

    Pipe line???

    Here is an interesting post from the SI board:

    IBD's Feb. 13 edition reports the top 10 holdings, buys & sells of 3 healthcare funds. ABT is among the top 10 holdings of
    two funds: Fidelity Select Healthcare and Putnam Health Sciences. Fidelity has increased its holdings to 997K shares, 4.5% of
    its holdings, while Putnam has decreased its holdings to 1.28 mil shares, 3.8% of its holdings. ABT is the top sell of Vanguard
    Specialized Health Care, the fund having dumped 2.09 mil shares. The time frame for all this activity is not indicated. Sure would like
    to know what scared Vanguard away.

    Also would love to know how the ABT-594 trials are going. Like Chuck Edwards (Jan 2 reply), I think it's a biggie. If the
    stuff works, they'll be selling it worldwide in a jiffy. Only the poor US patients will have to wait for relief. Anecdotal reports
    should be available as the trial progresses. Investors, at least certain investors, won't have to wait for a formal announcement on
    this one. The patient will tell the nurse "I feel great and the side effects are gone! Get my broker on the phone, immediately."
    Will be pretty hard to keep it quiet. Anybody know where the trials are being conducted? Maybe we should start dating the nurses.

    SortNewest  |  Oldest  |  Most Replied Expand all replies
    • You mentioned: "IBD's Feb. 13 edition..." What's IBD?

    • I have access to Pharmaprojects. I will check the progress of the drug and post on Wednesday when I am in the office. In terms of figuring out where the clin trials are being conducted, check out While the candidate drug names are usually not mentioned, if you look in the right category, you can usually figure out what is going on.

      Finally, a general comment about narcotic analgesics. The potential of a product can be limited if the product is found to have addictive properties. Look at what is happening to ULTRAM, (a J&J drug) and DURACT, (a Novartis drug). If they go on restrictive schedules, then the product potential goes down considerably. I should note that I do not know ANYTHING about the properties of the Abbott drug to know what class of products it falls into, and anything about its mechanism of action.

      • 1 Reply to cwdonald
      • CW, thank you for the link to that neat site! I've sent away for their New Therapies newsletter. Such a deal! Unfortunaely, it's not too helpful in locating the ABT-594 test location. Seems they only list domestic trials while ABT-594 is being tested in Britain I believe. Hope you can find it in Pharmaprojects. Regards, Dragonfly.

42.9001-0.1899(-0.44%)2:10 PMEDT

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.